DSIJ Mindshare

3:1 Bonus Share & FIIs took a fresh entry in this low PE, high ROE & high ROCE multibagger pharma stock under Rs 80; PAT zooms over 500 per cent

The stock gave multibagger returns of 1,460 per cent in 2 years, 2,300 per cent in 3 years and a whopping 14,200 per cent in 5 years.

Kiran Shroff 0 14202 Article rating: 3.8

The stock gave multibagger returns of 1,460 per cent in 2 years, 2,300 per cent in 3 years and a whopping 14,200 per cent in 5 years.

Penny Stock Under Rs 5: Don't Miss Out on the Micro-Cap's Major News!

This groundbreaking technology has the potential for eliminating the need for painful injections.

Aniket Gogate 0 1510 Article rating: 3.0

Transgene Biotek Ltd.'s partnership with NiedlFree Technologies has the potential to revolutionize the way people with diabetes manage their condition. Oral insulin delivery could eliminate the need for painful injections and make it easier for people to adhere to their treatment plans. This could lead to improved health outcomes and a better quality of life for millions of people worldwide.

Stock in focus: Pharma company hits milestone with successful Phase I study of DRL_TC a tocilizumab biosimilar; get full story here!

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over the counter medications.

Siddharth Mane 0 938 Article rating: 4.7

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.

Multibaggers of 2022: These pharmaceutical stocks more than doubled the wealth of investors! Do you own them?

After a prolonged correction, the index underwent another surge in recent times as healthcare stocks gained momentum due to the deteriorating Covid scenario.

Mandar Wagh 0 619 Article rating: 5.0

After a prolonged correction, the index underwent another surge in recent times as healthcare stocks gained momentum due to the deteriorating Covid scenario. 

Advent International buys more than 50 per cent stake for Rs 6300 crore in this pharma company. Do you own it?

Advent is expected to buy 51 per cent of the promoter’s stake in the company and launch an open offer for an additional 26 per cent

Bhavya Rathod 0 1229 Article rating: 4.3

The company released a press release on Monday, stating Advent International has entered into definitive agreement to acquire significant stake in the company and intends to explore the merger of  its portfolio company

RSS
123
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR